At the Core of the Latest Pharm-to-Table Dispute: Which GLP-1 Was Hims Preferring?
Shares:
As is tradition, Merck is out as the first company to talk about 2023 list- and net-price changes across its portfolio. The company dropped its annual Pricing Action Transparency Report
And here, I thought I’d get the last Curve of the week out in the morning. Thanks for your patience. And thanks to Jennifer Kim, Josh Schimmer, and my fellow
A quick note: The number of folks who opened Cost Curve yesterday fell precipitously. I’m not worried about the statistics, but I do suspect that the experimentation with the easier-to-read